Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mengyi Lu

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Biostatistics (Oxford, England)|September 14, 2024
A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimesMengyi Lu, Ying Yuan, Suyu Liu
Contemporary Clinical Trials|May 7, 2022
Why there are so many contradicted or exaggerated findings in highly-cited clinical research?Mengyi Lu, Suyu Liu, Ying Yuan
Statistics in Biopharmaceutical Research|May 5, 2025
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination TrialsMengyi Lu, Jingyi Zhang, Ying Yuan, et al.
BMC Medical Research Methodology|March 7, 2026
Time to benefit estimation in multicenter studies using flexible hazard shared frailty modelsMengyi Lu, Zhuoyue Wu, Yang Zhao, et al.
Statistics in Biopharmaceutical Research|June 17, 2026
An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class ModelJiaying Guo, Mengyi Lu, Yan Han, et al.
Statistics in Biopharmaceutical Research|June 17, 2026
A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priorsMu Shan, Mengyi Lu, Leng Han, et al.
China CDC Weekly|May 16, 2025
A Novel Adaptive Design Approach for Early-Phase Clinical Trials to Optimize Vaccine DosageXin Tong, Dongfang You, Fang Shao, et al.
Cancer Management and Research|March 6, 2023
The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian CarcinomaQianqian Pan, Mingjing Wei, Mengyi Lu, et al.
China CDC Weekly|December 30, 2024
Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza VaccinationDongfang You, Yi Zhou, Yan Yan, et al.
Pharmaceutical Statistics|June 26, 2024
T3 + 3: 3 + 3 Design With Delayed OutcomesJiaying Guo, Mengyi Lu, Isabella Wan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biostatistics (Oxford, England)|September 14, 2024
A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimesMengyi Lu, Ying Yuan, Suyu Liu
Contemporary Clinical Trials|May 7, 2022
Why there are so many contradicted or exaggerated findings in highly-cited clinical research?Mengyi Lu, Suyu Liu, Ying Yuan
Statistics in Biopharmaceutical Research|May 5, 2025
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination TrialsMengyi Lu, Jingyi Zhang, Ying Yuan, et al.
BMC Medical Research Methodology|March 7, 2026
Time to benefit estimation in multicenter studies using flexible hazard shared frailty modelsMengyi Lu, Zhuoyue Wu, Yang Zhao, et al.
Statistics in Biopharmaceutical Research|June 17, 2026
An Adaptive Biomarker-based Umbrella Trial Design Using Bayesian Latent Class ModelJiaying Guo, Mengyi Lu, Yan Han, et al.
Statistics in Biopharmaceutical Research|June 17, 2026
A Bayesian Adaptive Marker-Stratified Design for Phase II Clinical Trials Using Calibrated Spike-and-Slab priorsMu Shan, Mengyi Lu, Leng Han, et al.
China CDC Weekly|May 16, 2025
A Novel Adaptive Design Approach for Early-Phase Clinical Trials to Optimize Vaccine DosageXin Tong, Dongfang You, Fang Shao, et al.
Cancer Management and Research|March 6, 2023
The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian CarcinomaQianqian Pan, Mingjing Wei, Mengyi Lu, et al.
China CDC Weekly|December 30, 2024
Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza VaccinationDongfang You, Yi Zhou, Yan Yan, et al.
Pharmaceutical Statistics|June 26, 2024
T3 + 3: 3 + 3 Design With Delayed OutcomesJiaying Guo, Mengyi Lu, Isabella Wan, et al.
Pageof 3